TriPath Imaging has entered into a new three-year agreement with Laboratory Corporation of America (LabCorp) to provide the SurePath test pack and the PrepStain slide processor for cervical cancer screening.

LabCorp first introduced the SurePath liquid-based Pap test in 1999. Additional terms of the agreement were not disclosed.

“We are very pleased to have signed a new multi-year agreement with LabCorp,” said Paul Sohmer, chairman, president and CEO of TriPath. “We look forward to continuing to build on the strong relationship that we have enjoyed for the past few years with LabCorp. We expect that our new agreement will create value for both companies.”

Burlington-based LabCorp is one of the world’s largest clinical laboratories, with annual revenues of $2.5 billion in 2002 and more than 24,000 employees.

TriPath, also based in Burlington, develops manufactures, markets and sells solutions to improve the clinical management of cancer, including detection, diagnosis, staging and treatment.